122 related articles for article (PubMed ID: 23597579)
41. Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.
Oppermann S; Lam AJ; Tung S; Shi Y; McCaw L; Wang G; Ylanko J; Leber B; Andrews D; Spaner DE
Oncotarget; 2016 Nov; 7(45):72608-72621. PubMed ID: 27579615
[TBL] [Abstract][Full Text] [Related]
42. CLL in focus: news in the treatment of chronic lymphocytic leukemia.
Schuyler D
Clin Adv Hematol Oncol; 2020 Oct; 18(10):627-628. PubMed ID: 33201868
[No Abstract] [Full Text] [Related]
43. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable
Golay J; Ubiali G; Introna M
Haematologica; 2017 Oct; 102(10):e400-e403. PubMed ID: 28642301
[No Abstract] [Full Text] [Related]
44. From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.
Lorenz J; Waldschmidt J; Wider D; Follo M; Ihorst G; Chatterjee M; May AM; Duyster J; Rosenwald A; Wäsch R; Zirlik K; Engelhardt M
Br J Haematol; 2016 Sep; 174(6):985-9. PubMed ID: 26491948
[No Abstract] [Full Text] [Related]
45. Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.
Kazi JU; Kabir NN; Rönnstrand L
Med Oncol; 2013 Dec; 30(4):757. PubMed ID: 24174318
[TBL] [Abstract][Full Text] [Related]
46. Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia?
Decker T
Leuk Lymphoma; 2008 Dec; 49(12):2235-6. PubMed ID: 19052968
[No Abstract] [Full Text] [Related]
47. Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin.
Dürr C; Hanna BS; Schulz A; Lucas F; Zucknick M; Benner A; Clear A; Ohl S; Öztürk S; Zenz T; Stilgenbauer S; Li-Weber M; Krammer PH; Gribben JG; Lichter P; Seiffert M
Haematologica; 2018 Apr; 103(4):688-697. PubMed ID: 29326123
[TBL] [Abstract][Full Text] [Related]
48. Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.
Efremov DG; Wiestner A; Laurenti L
Mediterr J Hematol Infect Dis; 2012; 4(1):e2012067. PubMed ID: 23170196
[TBL] [Abstract][Full Text] [Related]
49. "Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''.
Oppezzo P; Dighiero G
Blood Cancer J; 2013 Sep; 3(9):e149. PubMed ID: 24056719
[TBL] [Abstract][Full Text] [Related]
50. Kinase inhibitors in CLL: drawing the roadmap.
Fowler N
Blood; 2021 May; 137(20):2717-2719. PubMed ID: 34014294
[No Abstract] [Full Text] [Related]
51. Cell Trafficking in Chronic Lymphocytic Leukemia.
Davids MS; Burger JA
Open J Hematol; 2012; 3(S1):. PubMed ID: 22844583
[TBL] [Abstract][Full Text] [Related]
52. New emerging therapies in the management of chronic lymphocytic leukemia.
Li XL; Zhang CX
Oncol Lett; 2016 Nov; 12(5):3051-3054. PubMed ID: 27899962
[TBL] [Abstract][Full Text] [Related]
53. New Agents to Treat Chronic Lymphocytic Leukemia.
Walter HS; Salles GA; Dyer MJ
N Engl J Med; 2016 Jun; 374(22):2185-6. PubMed ID: 27248633
[No Abstract] [Full Text] [Related]
54. Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib.
Sharman J; Di Paolo J
Ther Adv Hematol; 2016 Jun; 7(3):157-70. PubMed ID: 27247756
[TBL] [Abstract][Full Text] [Related]
55. Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL.
Bruch PM; Giles HA; Kolb C; Herbst SA; Becirovic T; Roider T; Lu J; Scheinost S; Wagner L; Huellein J; Berest I; Kriegsmann M; Kriegsmann K; Zgorzelski C; Dreger P; Zaugg JB; Müller-Tidow C; Zenz T; Huber W; Dietrich S
Mol Syst Biol; 2022 Aug; 18(8):e10855. PubMed ID: 35959629
[TBL] [Abstract][Full Text] [Related]
56. All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic Leukemia.
Thompson MC; Roeker LE; Mato AR
Haematologica; 2021 Sep; 106(9):2300-2301. PubMed ID: 33730846
[No Abstract] [Full Text] [Related]
57. BTKi bonanza in CLL/SLL: Sorting out the differences.
Hampel PJ; Parikh SA
Am J Hematol; 2023 Apr; 98(4):556-559. PubMed ID: 36691752
[No Abstract] [Full Text] [Related]
58. Occupy BTK: the key to controlling CLL.
Thompson PA
Blood; 2020 Jul; 136(1):4-6. PubMed ID: 32614961
[No Abstract] [Full Text] [Related]
59. Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Sana I; Mantione ME; Angelillo P; Muzio M
Front Oncol; 2021; 11():651057. PubMed ID: 33869054
[TBL] [Abstract][Full Text] [Related]
60. New responsibilities for aged kinases in B-lymphomas.
Piazza F; Manni S; Arjomand A; Visentin A; Trentin L; Semenzato G
Hematol Oncol; 2020 Feb; 38(1):3-11. PubMed ID: 31782972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
